Frankfurt
12.05.26 | 17:18
1,034 Euro
+14,63 % +0,132
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.05. | Advicenne Announces the Opening of a Safeguard Proceedings to Restructure Its Financial Liabilities and Finalize the Extension of Its Cash Runway | 433 | Business Wire | A proactive initiative to restructure the Company's debt A protective framework that allows for the continuation of commercial, clinical, and regulatory activities, as well as discussions... ► Artikel lesen | |
| 24.04. | ADVICENNE: Advicenne 2025 Universal Registration Document made available | 1 | Euronext | ||
| 24.04. | Advicenne 2025 Universal Registration Document Made Available | 326 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 26.03. | Advicenne Reports Its 2025 Annual Financial Results | 3.177 | Business Wire | Product sales up 18.7% to €5.8 million
European end-market sales of Sibnayal rose by more than 71% to nearly €11 million
Royalties doubled to over €1.1 million
Cash position... ► Artikel lesen | |
| 02.02. | Advicenne: Official Reimbursement of Sibnayal for the Treatment of dRTA in France | 1.398 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 27.01. | Advicenne Receives Marketing Authorization and Reimbursement for Sibnayal in UAE | 409 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| ADVICENNE Aktie jetzt für 0€ handeln | |||||
| 22.01. | Advicenne: 2025 Full Year Sales | 474 | Business Wire | 2025 sales totaled €5.73m, up 18.4%
Sibnayal sales rose 36.6% to €3.01m
2025 Royalties are estimated at €1m, double the amount for 2024
End-markets estimated sales of Sibnayal... ► Artikel lesen | |
| 20.01. | Advicenne: 2026 Financial Calendar | 422 | Business Wire | Regulatory News:
Advicenne(Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 19.01. | Advicenne's Sibnayal NDA For DRTA Tratement Accepted For Review By FDA | 2 | RTTNews | ||
| 19.01. | Advicenne: FDA Has Accepted for Review the Marketing Authorization Application for Sibnayal in the United States for the Treatment of dRTA | 330 | Business Wire | The US regulatory agency has set the target date for the final approval decision, known as the PDUFA date, as of September 3rd, 2026.
Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746... ► Artikel lesen | |
| 12.01. | Advicenne Has Successfully Renewed the Marketing Authorization of Sibnayal in European Union | 314 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 04.11.25 | Advicenne Has Submitted to US FDA the Registration Application for Sibnayal in dRTA Treatment | 514 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 19.09.25 | Advicenne Reports First Half Financial Results as of June 30, 2025, and Updates on Its Activities | 575 | Business Wire | Sibnayal® end-market sales (Europe and Middle East) up 103% to €5.5 million
H1 products sales and royalties totaled €3.1 million, up 20%
Financial visibility extended to the fourth... ► Artikel lesen | |
| 26.08.25 | Advicenne Announces the Publication in Orphanet Journal of Rare Diseases of the Long-term European Study Results of dRTA Treatment Using ADV7103 | 419 | Business Wire | This extensive clinical dataset serves ADV7103 registration dossier in the United States of America, expected to be submitted in Q4 2025
Regulatory News:
Advicenne (Euronext Growth Paris... ► Artikel lesen | |
| 28.07.25 | Advicenne Receives Marketing Authorization and Reimbursement for Sibnayal in Saudi Arabia | 587 | Business Wire | Regulatory News:
Advicenne (Euronext Growth® FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare... ► Artikel lesen | |
| 25.07.25 | Advicenne Reports its H1 2025 Sales | 513 | Business Wire | Regulatory News:
Advicenne (Euronext Growth FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney... ► Artikel lesen | |
| 21.07.25 | Advicenne Raises 2.6 Million Euros in Its Capital Increase and Extends Its Financial Visibility | 952 | Business Wire | Subscription of €2.6 million, representing 100% of the initial amount Financial horizon extended to the end of Q3 2026 thanks to concomitant financial restructuring Bpifrance now... ► Artikel lesen | |
| 02.07.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.07.2025 | 526 | Xetra Newsboard | Das Instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY wird ex Kapitalmassnahme gehandelt am 02.07.2025 The instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY is traded ex capital... ► Artikel lesen | |
| 30.06.25 | Advicenne Confirms the Upcoming Filing for Registration of ADV7103 in the USA and is Securing Its Financing Through Loan Restructuring and the Launch of a Rights Issue. | 550 | Business Wire | Submission of the US marketing authorization application for ADV7103 planned in Q4 2025, following positive feedback from the FDA on the additional data submitted. Repayment of tranches... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 22,040 | -0,05 % | JEFFERIES stuft PFIZER INC auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat Pfizer mit einem Kursziel von 35 US-Dollar auf "Buy" belassen. Der Pharmakonzern habe im ersten Quartal positiv überrascht und die Jahresziele... ► Artikel lesen | |
| ABBVIE | 177,45 | +0,20 % | Ihre wichtigsten Termine: Heute im Fokus: AbbVie, Colgate-Palmolive, Toyota, Sony, Krones, Bechtle, Evonik | © Foto: Hiro Komae/AP/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 05:00... ► Artikel lesen | |
| HAEMATO | 12,000 | -4,00 % | M1 Kliniken schließt Verkauf von Haemato Pharm ab | Die M1 Kliniken AG hat den Verkauf der Haemato Pharm GmbH über ihre Mehrheitsbeteiligung Haemato AG an die Phoenix Group mit Wirkung zum Ablauf des 31. Januar 2026 abgeschlossen. Sämtliche Vollzugsbedingungen... ► Artikel lesen | |
| HALEON | 3,893 | +1,75 % | Haleon PLC - Transactions in Own Shares | ||
| ACHIEVE LIFE SCIENCES | 5,000 | -2,91 % | Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma | SEATTLE and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve and the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 182,00 | -4,21 % | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement | $15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing total capital received from Ligand to $40 million to date in exchange for tiered royalty... ► Artikel lesen | |
| ROYALTY PHARMA | 45,000 | +6,30 % | Royalty Pharma Q1 Profit, Revenue Increase; Raises Full-year Portfolio Receipts Outlook | WASHINGTON (dpa-AFX) - Royalty Pharma plc (RPRX) on Thursday reported higher first-quarter earnings, supported mainly by growth in income from financial royalty assets.Net income before tax... ► Artikel lesen | |
| EISAI | 24,520 | -1,76 % | Eisai, Biogen Say FDA Extends Review Of LEQEMBI IQLIK As A Starting Dose For Early AD | WESTON (dpa-AFX) - Eisai Co. Ltd (ESALY.PK) and Biogen Inc. (BIIB) on Friday said the U.S. Food and Drug Administration has extended by three months the review of LEQEMBI IQLIK as a starting... ► Artikel lesen | |
| TG THERAPEUTICS | 36,600 | +0,83 % | TG THERAPEUTICS, INC. - 10-Q, Quarterly Report | ||
| DR REDDYS | 10,700 | -6,14 % | Stocks to Watch Today (May 13, 2026): Vodafone Idea, Bharti Airtel, Dr Reddy's, Tata Power, Dixon Tech and more | ||
| BETTERLIFE PHARMA | 0,035 | 0,00 % | BetterLife Pharma Inc.: BetterLife Pharma to Participate in YAFO Capital Access Asia Partnering Forum During JPM Week in San Francisco | Vancouver, British Columbia--(Newsfile Corp. - January 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biopharmaceutical company... ► Artikel lesen | |
| ENTOURAGE HEALTH | - | - | Ontario Securities Commission: OSC bans WeedMD ex Carr, again | ||
| WAVE LIFE SCIENCES | 5,850 | +0,86 % | Wave Life Sciences Ltd.: Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update | With recent FDA acceptance of the Phase 2a multidose portion of INLIGHT trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with higher BMI, with and without type 2 diabetes, this portion of the... ► Artikel lesen | |
| KYOWA KIRIN | 12,400 | -1,59 % | Kyowa Kirin Co., Ltd. Reports Climb In Q1 Bottom Line | WASHINGTON (dpa-AFX) - Kyowa Kirin Co., Ltd. (KYKOY) revealed earnings for its first quarter that Increases, from the same period last yearThe company's earnings came in at JPY12.034 billion... ► Artikel lesen | |
| IGC PHARMA | 0,270 | +7,14 % | IGC Pharma, Inc.: IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase | Outreach initiative supports awareness of agitation and patient engagement as enrollment approaches completion POTOMAC, MD / ACCESS Newswire / April 28, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC"... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADVICENNE finden Sie auf Wallstreet Online.